Synthetic Lethality in Cancer Therapeutics: The Next Generation
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Synthetic lethality (SL) provides a conceptual framework for tackling targets that are not classically “druggable,” including loss-of-function mutations in tumor suppressor genes required for carcinogenesis. Recent technological advances have led to an inflection point in our understanding of genetic interaction networks and ability to identify a wide array of novel SL drug targets. Here, we review concepts and lessons emerging from first-generation trials aimed at testing SL drugs, discuss how the nature of the targeted lesion can influence therapeutic outcomes, and highlight the need to develop clinical biomarkers distinct from those based on the paradigms developed to target activated oncogenes.Significance: SL offers an approach for the targeting of loss of function of tumor suppressor and DNA repair genes, as well as of amplification and/or overexpression of genes that cannot be targeted directly. A next generation of tumor-specific alterations targetable through SL has emerged from high-throughput CRISPR technology, heralding not only new opportunities for drug development, but also important challenges in the development of optimal predictive biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 3×
“Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.”
BackgroundThe cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Next-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047 · cited 1×
“In addition to its role in DNA damage signaling, ATM has a key gatekeeper role via regulation of p53 stabilization in response to cellular stress (104); inactivation of ATM appears to suppress p53 signaling to a degree that is sufficient for tumorigenesis, evidenced by the observation that LOF alterations in ATM and T…”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors
Anzalone, A. V., Koblan, L. W., & Liu, D. R. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0561-9 · Cited by 2,237
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820
High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.
Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.015 · Cited by 1,571
Self-citationPrioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1103-9 · Cited by 1,338
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147 · cited 1×
“Conversely, in vivo application of CRISPR-based screening tools may also prove to be useful in identifying cancer cell targets that stimulate host immunity and/or synergize with checkpoint blockade; in addition to recovering PD-L1, a recent in vivo genetic screening approach was used to identify unanticipated candidat…”
BackgroundPooled CRISPR screening with single-cell transcriptome readout.
Datlinger, P., Rendeiro, A. F., Schmidl, C., Krausgruber, T., Traxler, P., Klughammer, J., Schuster, L. C., Kuchler, A., Alpar, D., & Bock, C. (2017) · Nature Methods · doi:10.1038/nmeth.4177 · Cited by 1,096 · cited 1×
“The development of single-cell technologies to assay the transcriptome of individual cells while simultaneously retrieving guide RNA sequences present in each cell has also allowed investigators to link CRISPRmediated perturbations with transcriptional phenotypes (37,38).”
BackgroundSecondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Davies, H., Glodzik, D., Morganella, S., Yates, L. R., Staaf, J., Zou, X., Ramakrishna, M., Martin, S., Boyault, S., Sieuwerts, A. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4292 · Cited by 1,086 · cited 4×
“For example, markers that quantify genomic ‘scarring’ have shown to be sensitive for the detection of tumors harboring biallelic HR gene inactivation (65,66), but have nevertheless been limited by modest positive-predictive value and the inability to provide a ‘real-time’ readout of phenotype, as the emergence of drug…”
BackgroundInfluentialResistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Self-citationGene essentiality and synthetic lethality in haploid human cells
Blomen, V. A., Májek, P., Jae, L. T., Bigenzahn, J. W., Nieuwenhuis, J., Staring, J., Sacco, R., van Diemen, F. R., Olk, N., Stukalov, A., et al. (2015) · Science · doi:10.1126/science.aac7557 · Cited by 857 · cited 1×
“Notably, prior analyses of context-specific genetic dependencies identified in pancancer cell line LOF genomic screens have shown them to be highly enriched for SL interactions (18,19).”
BackgroundSurvival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792
Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743
Abida, W., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., Sautois, B., Vogelzang, N. J., Bambury, R. M., Voog, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01035 · Cited by 694
McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600
Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., & Varmus, H. E. (2001) · Genes & Development · doi:10.1101/gad.947701 · Cited by 582
A Genetic Map of the Response to DNA Damage in Human Cells
Olivieri, M., Cho, T., Álvarez-Quilón, A., Li, K., Schellenberg, M. J., Zimmermann, M., Hustedt, N., Rossi, S. E., Adam, S., Melo, H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.040 · Cited by 551
Self-citationPolak, P., Kim, J., Braunstein, L. Z., Karlic, R., Haradhavala, N. J., Tiao, G., Rosebrock, D., Livitz, D., Kübler, K., Mouw, K. W., et al. (2017) · Nature Genetics · doi:10.1038/ng.3934 · Cited by 531
Combinatorial single-cell CRISPR screens by direct guide RNA capture and targeted sequencing
Replogle, J. M., Norman, T. M., Xu, A., Hussmann, J. A., Chen, J., Cogan, J. Z., Meer, E. J., Terry, J. M., Riordan, D. P., Srinivas, N., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0470-y · Cited by 465 · cited 1×
“The development of single-cell technologies to assay the transcriptome of individual cells while simultaneously retrieving guide RNA sequences present in each cell has also allowed investigators to link CRISPRmediated perturbations with transcriptional phenotypes (37,38).”
BackgroundWRN helicase is a synthetic lethal target in microsatellite unstable cancers
Chan, E. M., Shibue, T., McFarland, J. M., Gaeta, B., Ghandi, M., Dumont, N., Gonzalez, A., McPartlan, J. S., Li, T., Zhang, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1102-x · Cited by 458 · cited 3×
“Clin Cancer Res 2020;26(11):2487–96 doi 10.”
BackgroundFunctional genomic landscape of cancer-intrinsic evasion of killing by T cells
Lawson, K. A., Sousa, C. M., Zhang, X., Kim, E., Akthar, R., Caumanns, J. J., Yao, Y., Mikolajewicz, N., Ross, C., Brown, K. R., et al. (2020) · Nature · doi:10.1038/s41586-020-2746-2 · Cited by 443 · cited 2×
“Nat Biotechnol 2020;38(7):824–44 doi 10.”
Passenger deletions generate therapeutic vulnerabilities in cancer
Muller, F. L., Colla, S., Aquilanti, E., Manzo, V. E., Genovese, G., Lee, J., Eisenson, D., Narurkar, R., Deng, P., Nezi, L., et al. (2012) · Nature · doi:10.1038/nature11331 · Cited by 339 · cited 1×
“Deletions occurring at tumor suppressor loci can also extend beyond the bona fide driver genes, which may allow identification of genetic or pharmacological sensitivities caused by gene loss that is collateral to the actual cancerdriving event (80,81).”
BackgroundSystematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells
Dong, M. B., Wang, G., Chow, R. D., Ye, L., Zhu, L., Dai, X., Park, J. J., Kim, H. R., Errami, Y., Guzman, C. D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.044 · Cited by 330 · cited 1×
“High-throughput in vivo CRISPR screens in primary CD8+ T-cells have been shown to allow for the discovery of negative regulators of anti-tumor T-cell immunity, as evidenced by their ability to recover known immunotherapy targets such as PD-1 and Tim-3 (42).”
BackgroundCRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities
Han, K., Pierce, S. E., Li, A., Spees, K., Anderson, G. R., Seoane, J. A., Lo, Y.-H., Dubreuil, M., Olivas, M., Kamber, R. A., et al. (2020) · Nature · doi:10.1038/s41586-020-2099-x · Cited by 311 · cited 1×
“Additional recent work has highlighted the use of 3D culture systems in genetic interaction screens in improving the recapitulation of in vivo phenotypes as compared to traditional 2D screen, as illustrated by the their greater accuracy in the assessment of growth advantage resulting from the knocking-out of tumor sup…”
BackgroundOrthologous CRISPR–Cas9 enzymes for combinatorial genetic screens
Najm, F. J., Strand, C., Donovan, K. F., Hegde, M., Sanson, K. R., Vaimberg, E. W., Sullender, M. E., Hartenian, E., Kalani, Z., Fusi, N., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4048 · Cited by 279 · cited 2×
“Moreover, the integration of tools for both GOF (CRISPRa) and LOF (CRISPRi or CRISPR-mediated knockout) perturbations has facilitated the development of combined bidirectional screens for the concurrent identification of genetic interactions involving LOF and/or GOF alterations (28,34,35).”
BackgroundA tiling-deletion-based genetic screen for cis-regulatory element identification in mammalian cells
Diao, Y., Fang, R., Li, B., Meng, Z., Yu, J., Qiu, Y., Lin, K. C., Huang, H., Liu, T., Marina, R. J., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4264 · Cited by 259 · cited 1×
“Although originally developed to study regulatory elements and long non-coding RNAs (lncRNAs) through generation of kilobase-long deletions (30,31), the development of dual- or multigRNA libraries has additionally facilitated multiplexing of ‘query’ gRNAs to uncover genetic interactions that would otherwise be obscure…”
BackgroundGenome-Scale CRISPR Screening in Human Intestinal Organoids Identifies Drivers of TGF-β Resistance
Ringel, T., Frey, N., Ringnalda, F., Janjuha, S., Cherkaoui, S., Butz, S., Srivatsa, S., Pirkl, M., Russo, G., Villiger, L., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.02.007 · Cited by 202
Collateral lethality: a new therapeutic strategy in oncology
Muller, F. L., Aquilanti, E. A., & DePinho, R. A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.002 · Cited by 132 · cited 1×
“Deletions occurring at tumor suppressor loci can also extend beyond the bona fide driver genes, which may allow identification of genetic or pharmacological sensitivities caused by gene loss that is collateral to the actual cancerdriving event (80,81).”
BackgroundConditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies
Mina, M., Raynaud, F., Tavernari, D., Battistello, E., Sungalee, S., Saghafinia, S., Laessle, T., Sanchez-Vega, F., Schultz, N., Oricchio, E., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.010 · Cited by 129
The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers
Weigelt, B., Bi, R., Kumar, R., Blecua, P., Mandelker, D. L., Geyer, F. C., Pareja, F., James, P. A., kConFab Investigators, Couch, F. J., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy028 · Cited by 128 · cited 1×
“In addition to its role in DNA damage signaling, ATM has a key gatekeeper role via regulation of p53 stabilization in response to cellular stress (104); inactivation of ATM appears to suppress p53 signaling to a degree that is sufficient for tumorigenesis, evidenced by the observation that LOF alterations in ATM and T…”
BackgroundSelf-citation
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
“Tumor cells often have altered metabolic pathways that can create unique vulnerabilities [31, 32].”
BackgroundEngineered cellular immunotherapies in cancer and beyond
Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G., & June, C. H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01765-8 · Cited by 269
Adam, S., Rossi, S. E., Moatti, N., De Marco Zompit, M., Xue, Y., Ng, T. F., Álvarez-Quilón, A., Desjardins, J., Bhaskaran, V., Martino, G., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00266-w · Cited by 121
Self-citationSmith, H. L., Willmore, E., Mukhopadhyay, A., Drew, Y., & Curtin, N. J. (2022) · Cancers · doi:10.3390/cancers14225559 · Cited by 9
Metadata
- Authors
- Setton, J., Zinda, M., Riaz, N., Durocher, D., Zimmermann, M., Koehler, M., Reis-Filho, J. S., & Powell, S. N.
- Venue
- Cancer Discovery
- Published
- 2021-04-01
- Volume
- 11
- Issue
- 7
- Pages
- 1626-1635
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3146811394
- Cited by
- 206
- References
- 41
- FWCI
- 8.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.